Gastropraxis an der St. Barbara-Klinik

The Gastroenterology department at Gastropraxis an der St. Barbara‑Klinik is advancing care for ulcerative colitis by testing novel oral and biologic agents designed to induce remission and maintain disease control.

• Oral controlled‑ileocolonic‑release nicotinamide (CICR‑NAM) for mild to moderate ulcerative colitis
• Top‑down therapy with mirikizumab versus azathioprine in newly diagnosed moderate‑to‑severe ulcerative colitis

The trials seek to evaluate efficacy, safety, and long‑term outcomes, aiming to improve symptom relief, endoscopic healing, and overall quality of life for patients.